Cartesian Therapeutics, Inc. (RNAC)
7.43
+0.58
(+8.47%)
USD |
NASDAQ |
Jun 10, 16:00
7.40
-0.03
(-0.40%)
After-Hours: 05:55
Cartesian Therapeutics Gross Profit Margin (Quarterly) : -688.5% for March 31, 2026
Gross Profit Margin (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2026 | -688.5% |
| December 31, 2025 | 35.80% |
| September 30, 2025 | -34.07% |
| June 30, 2025 | -97.65% |
| March 31, 2025 | -5.09% |
| September 30, 2024 | 26.10% |
| June 30, 2024 | 99.41% |
| March 31, 2024 | 96.87% |
| December 31, 2023 | 96.71% |
| September 30, 2023 | 97.11% |
| June 30, 2023 | 88.07% |
| March 31, 2023 | 89.63% |
| December 31, 2022 | 96.39% |
| September 30, 2022 | 97.40% |
| June 30, 2022 | 98.73% |
| March 31, 2022 | 98.11% |
| December 31, 2021 | 0.00% |
| September 30, 2021 | 0.00% |
| June 30, 2021 | 0.00% |
| March 31, 2021 | 0.00% |
| December 31, 2020 | 0.00% |
| Date | Value |
|---|---|
| September 30, 2020 | 0.00% |
| June 30, 2020 | |
| March 31, 2020 | |
| December 31, 2019 | 0.00% |
| September 30, 2019 | |
| June 30, 2019 | 0.00% |
| March 31, 2019 | 0.00% |
| December 31, 2018 | 0.00% |
| September 30, 2018 | |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 0.00% |
| September 30, 2017 | 0.00% |
| June 30, 2017 | 0.00% |
| March 31, 2017 | 0.00% |
| December 31, 2016 | 0.00% |
| September 30, 2016 | 0.00% |
| June 30, 2016 | 0.00% |
| March 31, 2016 | 0.00% |
| March 31, 2015 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| C4 Therapeutics, Inc. | 70.72% |
| Arrowhead Pharmaceuticals, Inc. | 91.36% |
| Oncolytics Biotech, Inc. | -- |
| Sangamo Therapeutics, Inc. | 39.18% |
| Sarepta Therapeutics, Inc. | 83.67% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | -43.23% |
| Profit Margin (Quarterly) | -50.23K% |
| Operating Margin (Quarterly) | -33.97K% |
| Return on Net Operating Assets | -78.25% |